Sareum Holdings PLC US Patent Allowance: SDC-1802 TYK2/JAK1 Inhibitor (4377B)
08 October 2020 - 5:00PM
UK Regulatory
TIDMSAR
RNS Number : 4377B
Sareum Holdings PLC
08 October 2020
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
US Patent Allowance for Sareum's SDC-1802 TYK2/JAK1
Inhibitor
Cambridge, UK, 8 October 2020 - Sareum Holdings plc (AIM: SAR),
the specialist drug development company delivering targeted small
molecule therapeutics to improve the treatment of cancer and
autoimmune diseases, is pleased to announce that the United States
Patent and Trademark Office has issued a Notice of Allowance for a
patent in respect of an invention associated with Sareum's
proprietary SDC-1802 TYK2/JAK1 Kinase Inhibitor Programme (the
"SDC-1802 Programme"). This programme is in preclinical development
and targets cancer and cancer immunotherapy.
The patent (US Patent Application no. 16/351,620) will protect
the SDC-1802 molecule and pharmaceutical preparations thereof.
Subject to certain formalities being completed, the Company expects
that the patent will be granted within three months. Following the
grant of this patent, Sareum will have approved patent protection
in the US for its SDC-1802 Programme and the grant will complete
the patent protection for this programme across all major
territories. This follows similar patent protection being granted
to the Company in Europe, announced on 10 November 2014, and in
Japan and China, announced on 19 December 2017.
Sareum's CSO, Dr John Reader, commented :
"The granting of this patent in the US will complete the
protection of the intellectual property for our proprietary
SDC-1802 Programme across all major markets. The Board believes
that the patent will enhance the value of its TYK2/JAK1 inhibitor
programmes and the Company's negotiating position as it continues
to engage in discussions with potential licence partners."
This announcement contains inside information for the purposes
of Article 7 of Regulation 596/2014.
For further information, please contact:
Sareum Holdings plc
Tim Mitchell, CEO 01223 497 700
Strand Hanson Limited (Nominated Adviser)
James Dance / Richard Tulloch 020 7409 3494
Hybridan LLP (Nominated Broker)
Claire Noyce / John Beresford-Peirse 020 3764 2341
Citigate Dewe Rogerson (Financial PR)
Mark Swallow/ David Dible 020 7638 9571
About Sareum
Sareum is a specialist drug development company delivering
targeted small molecule therapeutics to improve the treatment of
cancer and autoimmune diseases. The Company aims to generate value
through licensing its candidates to international pharmaceutical
and biotechnology companies at the preclinical or early clinical
trials stage.
Sareum is advancing internal programmes focused on distinct dual
tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through
preclinical development as therapies for autoimmune diseases,
including the "cytokine storm" immune system overreaction to
Covid-19 and other viral infections, (SDC-1801) and cancer
immunotherapy (SDC-1802).
The Company's preclinical FLT3+Aurora inhibitor programme
targeting haematological cancers is licensed to a China-based
specialty pharma company.
Sareum also has an economic interest in SRA737, a clinical-stage
oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets
cancer cell replication and DNA damage repair mechanisms.
Preliminary Phase 2 and comprehensive preclinical data suggest
SRA737 may have broad application in combination with other
oncology and immune-oncology drugs in genetically defined
patients.
SRA737 was discovered and initially developed by scientists at
The Institute of Cancer Research in collaboration with Sareum, and
with funding from Sareum and Cancer Research UK. SRA737 was
licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra
is currently exploring options to obtain the funding or support
necessary to advance the future development of SRA737.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the ticker SAR. For
further information, please visit the Company's website at www.sareum.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUPGPGUUPUGRM
(END) Dow Jones Newswires
October 08, 2020 02:00 ET (06:00 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2024 to May 2024
Sareum (LSE:SAR)
Historical Stock Chart
From May 2023 to May 2024